Trials / Completed
CompletedNCT00633932
Reflux Esophagitis Phase III Study (Initial Treatment)
A Multicentre, Randomised, Double-blind, Parallel-group, Comparative Study to Compare the Efficacy and Safety of Esomeprazole 20 mg and 40 mg Once Daily Oral Administration With Omeprazole 20 mg Once Daily Oral Administration in Patients With Reflux Esophagitis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 602 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This study is to evaluate the efficacy of esomeprazole 20 mg once daily and 40 mg once daily for 8 weeks on healing of Reflux Esophagitis in patients with reflux esophagitis in comparison with omeprazole 20 mg once daily by assessment of presence/absence of Reflux Esophagitis at Week 8 according to the Los Angeles classification .
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Esomeprazole | 20mg once daily |
| DRUG | Esomeprazole | 40 mg once daily |
| DRUG | Omeprazole | 20mg once daily |
Timeline
- Start date
- 2007-12-01
- Completion
- 2008-12-01
- First posted
- 2008-03-12
- Last updated
- 2010-12-20
- Results posted
- 2010-04-08
Locations
41 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00633932. Inclusion in this directory is not an endorsement.